What Is Actinium Pharmaceuticals, Inc. (ATNM) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Actinium Pharmaceuticals, Inc. 's intrinsic value is estimated at a composite fair value of $1.10. At a current market price of $0.92, 7 of 9 active valuation models identify upside potential, projecting an average implied return of +20.7%. Notably, Dynamic NAV sees the most upside at +82.1% (fair value: $1.67), while First Chicago is the most conservative at -83.0% ($0.16). The spread between these extremes — +165.1% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About ATNM?
9 of 13 models are currently active for ATNM. Of these, 7 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates ATNM's intrinsic value at $0.99, implying +8.7% upside from the current price. See which stocks rank higher →
How Does ATNM Rank in Biotechnology?
Among 76 Biotechnology stocks, ATNM ranks #25 by Quality of Company score. CirclFi's QOC score of 5.5/10 evaluates 32 fundamental signals. A score of 5.5 reflects mixed fundamentals.
See all Most Undervalued Biotechnology Stocks →
The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For Actinium Pharmaceuticals, Inc. , metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.
Is ATNM a Value Trap?
CirclFi's Value Trap algorithm assigns ATNM a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Actinium Pharmaceuticals, Inc. . Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Actinium Pharmaceuticals, Inc. scores 5.5 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +165.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ATNM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ATNM's 9 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad